PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).
Deborah Schrag(Dana-Farber Brigham Cancer Center), Harvey J. Mamon(Brigham and Women's Hospital), Thomas J. George(University of Florida Health), Joel E. Goldberg(Brigham and Women's Hospital), Jeffrey A. Meyerhardt(CancerCare), Leonard B. Saltz(Memorial Sloan Kettering Cancer Center), Alan P. Venook(University of California, San Francisco), Qian Shi(Mayo Clinic), George J. Chang(The University of Texas MD Anderson Cancer Center), Benjamin Musher(Baylor College of Medicine), Karyn A. Goodman(Icahn School of Medicine at Mount Sinai), Tareq Al Baghdadi(IHA Hematology Oncology Consultants), Marc J. Gollub(Memorial Sloan Kettering Cancer Center), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Jeffrey M. Farma(Fox Chase Cancer Center), Amylou C. Dueck(Mayo Clinic in Arizona), Ethan Basch(UNC Lineberger Comprehensive Cancer Center), Robert R. McWilliams(Mayo Clinic in Arizona), Hagen F. Kennecke(Virginia Mason Medical Center), Martin R. Weiser(Memorial Sloan Kettering Cancer Center)
Cited by 18
Related Papers
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k